Chymopapain-induced hypersensitivity following chemonucleolysis.
This study describes the changes in chymopapain-specific IgE antibody levels in patients following chemonucleolysis with Chymodiactin. Using the ChymoFAST method, chymopapain-specific IgE values were studied in 91 patients prior to and for 2 months post-Chymodiactin chemonucleolysis. A total of 8.8% (17/91) developed IgE levels greater than or equal to 0.06 IU/ml. Those patients with detectable IgE levels prior to chemonucleolysis were more likely than those with nondetectable preinjection levels (36.4% versus 4%) to develop chymopapain-specific IgE levels greater than or equal to 0.06 IU/ml.
D000918:Antibody Specificity; D002917:Chymopapain / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000276:immunology; D010450:Endopeptidases / Q000009:adverse effects*; D006801:Humans; D007124:Immunoenzyme Techniques; D007073:Immunoglobulin E / Q000032:analysis / Q000276:immunology*; D007405:Intervertebral Disc Displacement / Q000188:drug therapy*
D007073:Immunoglobulin E; D010450:Endopeptidases; D002917:Chymopapain